SIBYLLA®
Fold the future

Sibylla Biotech

Sibylla Biotech

Company Introduction

SIBYLLA® Fold the future

- Tech Development Milestone
- Venture Capital Investment
- Collaboration agreement

2017

Idea of a trailblazing approach to drug discovery, to address unmet medical needs using **protein folding simulation**

2019

Seed Investment € 2.4 M

- *in vitro* Platform Validation
- Pipeline Initiation

2021

Collaboration with **Takeda Pharmaceuticals**

2022

Series A Investment € 23 M

- *in vivo* Platform Validation
- Pipeline Value Creation

2023

Implementation of **AI**-based platform to accelerate discovery

2024

Collaboration agreement with a Pharma company (still undisclosed)

SIBYLLA
Fold the future

A New Targeting Protein Degradation Approach

PPI-FIT: Pharmacological Protein Inactivation by Folding Intermediate Targeting



Nascent Polypeptide

New class of **targets**:
folding intermediate states

Intermediate State

Druggable Pocket

New class of small molecules degraders:
Folding Interfering Degraders



Small Molecule

New **MoA** : degradation by the cellular quality-control machinery



Protein Degradation

Our approach represents an innovative drug discovery protocol that can be applied to undruggable proteins to address unmet needs

Key Differentiating Aspects

The PPI-FIT Approach is Well Differentiated from PROTACs and Glues

PROTACs



PROS:

- Can be identified rationally;
- Easy to achieve high potency.

CONS:

- Large compounds (not classical drug-like molecules);
- ADME difficult to optimize;
- Only applicable to ligandable proteins in the native state.

Molecular Glues



PROS:

- Small molecules with drug-like properties;
- Better ADME than PROTACs.

CONS:

- Difficult to identify using rational approaches;
- Usually identified by relying on target-agnostic screening.

Folding Interfering Degraders



PROS:

- Small molecules with drug-like properties;
- ADME easier to optimize as compared to PROTACs;
- Rational identification of degraders.

CONS:

- Very recent technology (less validated than the other two);
- Better-suited for proteins with short half-life.

SIBYLLA®
Fold the future

Sibylla's Drug Discovery & Development Platform

Proprietary protein folding simulation platform to discover new targets

Protein Folding → Druggable Pockets → Virtual Screening → Biology → Drug Design ⇄ Pharmacology → Drug Candidate



Sibylla's Unique Enabler Technology: Cotranslational Folding Simulations



Patented

SIBYLLA®
Fold the future

Sibylla's Drug Discovery & Development Platform

Proprietary AI-based platform to discover and optimize compounds

Protein Folding → Druggable Pockets → Virtual Screening → Biology → Drug Design ⇄ Pharmacology → Drug Candidate



Faster & more accurate proprietary pocket scouter



Faster screening of billion of compounds



Faster Drug Design



High quality data to train personalized & more accurate AI

Business Model

Dual Business Model: Licensing and Partnering

Licensing

Identification and optimization of hit compounds on a **proprietary pipeline** of **selected targets**.

Development up to **preclinical/clinical candidate** or **early clinical phase**.

Licensing: Preclinical / Clinical / Phase II candidates.

Partnering

Partnering our platform with **Pharma companies** interested in new disrupting technologies in the **targeted protein degradation** landscape to expand their own pipeline.

A discovery collaboration is in place with **Takeda Pharmaceutical.**

A discovery and development collaboration will soon be announced.

SIBYLLA
Fold the future

Lead Program

Identification of Folding Interfering Degraders Targeting Cyclin D1

Cyclin D1 (CCND1)





Therapeutic Area: **Oncology**
Breast, Non Small Cell Lung, Colorectal, etc.

Undruggable: first-in class and best-in-class opportunity

Market Size

Indication	Global Market Size
HR+ HER2- Breast Cancer	MARKETED CDK 4/6 inhibitors sales in 2022: Pfizer Ibrance (Palbociclib) **5,12 Billion USD** (-6%) Eli Lilly Verzenio (Abemaciclib) **2,48 Billion USD** (+84%) Novartis Kisqali (Ribociclib) **1,23 Billion USD** (+31%)
Breast Cancer	**28.8 Billion USD** in 2022, projected to reach 73.68 Billion USD by 2032 with Compound Annual Growth Rate (CAGR) of 9.8% between 2023 and 2032 (Precedence Research).
Non Small Cell Lung	**15.3 Billion USD** in 2021, projected to reach 36.9 Billion USD by 2031 with CAGR of 9.3% between 2022 and 2031 (Allied Market Research)
Colorectal	**16.29 Billion USD** in 2022, projected to increase from 17.05 Billion USD in 2023 to 23.03 Billion USD by 2030 with CAGR of 4.4% between 2023 and 2030 (Fortune Business Insights)
Multiple Myeloma	**21.6 Billion USD** in 2022, projected to reach 33.1 Billion USD by 2030 with CAGR of 6.3% between 2023 and 2030 (Vantage Market Research)

SIBYLLA® Fold the future

Status of Platform Validation

Accomplished objectives

Next objectives

Proceeding towards therapeutics while validating the platform

Protein Folding → Druggable Pockets → Virtual Screening → Biology → Drug Design ⇄ Pharmacology → Drug Candidate











2021

Folding simulation and pocket detection

2022

Hit ID (hit rate 5%)

MoA and biology on lead program

Target engagement on lead program

2023

Optimization

2024

in vivo PKPD

Selectivity Confirmation

2024

in vivo efficacy

2025

Drug candidate Nomination

SIBYLLA
Fold the future

Sibylla Biotech

Our People

Management

Lidia Pieri, PhD, MBA
Co-founder
Physicist
Entrepreneur
CEO

Giovanni Spagnolli, PhD
Co-founder
PPI-FIT developer
Biophysicist
Biochemist
CTO

Dominique Bridon, PhD
30+ years experience in drug discovery in pharma and biotech in US and EU
Executive Chairman

Sonia Poli, PhD
20 years experience in drug discovery and translational pharmacology in pharma and biotech
CSO

Advisors

Drug Discovery

VINCENZO SUMMA
MARIO VARASI

Biophysics

RADOSLAV ENCHEV

Pharma

PETER MAYCOX

Investors

Seroba. Investing in life sciences. Investing in life.

V-Bio Ventures

3B FUTURE Health Fund

CLARIS VENTURES

INDACO BIO

ViPARTNERS

cdp

VERTIS SGR
Private Equity & Venture Capital